Contineum Therapeutics
在场
Contineum Therapeutics 是一家在股票代码 CTNM (US) 下上市的公司。
高管
查看带有其 18 名主要高管的组织结构图
Contineum Therapeutics 搜索最多的简介
- Carmine Stengone, Director, President and Chief Executive Officer
- Troy Ignelzi, Director
- Sarah Boyce, Independent Member
高管在Contineum Therapeutics变化
- Sarah Boyce已作为Independent Member加入公司 (新闻发布的2024六月25号).
- John Healy已作为General Counsel and Corporate Secretary加入公司 (新闻发布的2024六月4号).
- Troy Ignelzi已作为Director加入公司 (新闻发布的2024五月21号).
创建提醒
跟踪 Contineum Therapeutics 的高管变动
生物技术
Contineum Therapeutics 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Chromocell的新名称是Channel Therapeutics Corporation。 (公布2024十一月22号).
- Enveda Biosciences 刚刚宣布为 130 筹款数百万美元。 (公布2024十一月22号).
- Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
生物技术 行业的其他推荐联系人
消息
Contineum Therapeutics 的最新新闻稿
- Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain | Contineum Therapeutics
- Contineum Therapeutics to Attend Upcoming Investor Conferences | Contineum Therapeutics
- News Releases | Contineum Therapeutics
- News Releases | Contineum Therapeutics
- Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | Contineum Therapeutics
- Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences | Contineum Therapeutics
- Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights | Contineum Therapeutics
- Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis | Contineum Therapeu
- Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors | Contineum Therapeutics
- View more press releases Close
通过电子邮件
